Research
Hormonal
Females have higher rates of insulin resistance than males from early childhood through mid-puberty, whereas males exhibit greater insulin resistance during late puberty and adulthood.
Insulin resistance changes differently for boys and girls as they grow. Girls tend to be more insulin resistant during early puberty, while boys become more resistant later. This biological difference contributes to why girls are more prone to type 2 diabetes in youth, while men are more prone in midlife.
GoodQualifiesHIGH confidence
females have higher rates of insulin resistance than males from early childhood through to mid-puberty, whilst, during late puberty and adulthood, males exhibit greater insulin resistance than females
Why this rating
Supported by insulin clamp studies in multiple ethnic groups (Caucasian, African-American, Latino).
Source
Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course
Amy G. Huebschmann et al. · Diabetologia · 2019
DOI 10.1007/s00125-019-4939-5
narrative_reviewCited 363×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes negates the natural cardiovascular protection typically afforded to premenopausal women, resulting in a 25–50% greater excess risk of incident cardiovascular disease in women compared to men with diabetes.Good
- Women with type 2 diabetes are undertreated for cardiovascular risk factors (HbA1c, blood pressure, lipids) compared to men, contributing to worse outcomes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →